These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38013293)

  • 1. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
    Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
    Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhu Q; Chen J; Zhao J; Zeng H
    BMC Cancer; 2024 Jul; 24(1):817. PubMed ID: 38978000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
    Stangl-Kremser J; Sun M; Ho B; Thomas J; Nauseef JT; Osborne JR; Molina A; Sternberg CN; Nanus DM; Bander NH; Tagawa S
    Prostate; 2023 Oct; 83(14):1351-1357. PubMed ID: 37424145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
    Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
    Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Man YN; Chen YF
    Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
    Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
    Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.
    Guan Y; Xiong H; Feng Y; Liao G; Tong T; Pang J
    Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):220-231. PubMed ID: 32034294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
    Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
    Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
    Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
    Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
    Pisano C; Tucci M; DI Stefano RF; Turco F; Samuelly A; Bungaro M; Vignani F; Tarenghi F; Scagliotti GV; DI Maio M; Buttigliero C
    Minerva Urol Nephrol; 2021 Dec; 73(6):803-814. PubMed ID: 33781017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
    PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index on short- and long-term outcome following surgery for spinal metastases.
    Ryvlin J; Kim SW; Hamad MK; Fourman MS; Eleswarapu A; Murthy SG; Gelfand Y; De la Garza Ramos R; Yassari R
    J Neurosurg Spine; 2024 Apr; 40(4):475-484. PubMed ID: 38157531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
    Flippot R; Telli T; Velev M; Fléchon A; De Vries-Brilland M; Turpin L; Bergman A; Turco F; Mahammedi H; Fendler WP; Giraudet AL; Josset Q; Montravers F; Vogel W; Gillessen S; Berardi Vilei S; Herrmann K; Kryza D; Paone G; Hadaschik B; Merlin C; Dufour PA; Bernard-Tessier A; Naoun N; Patrikidou A; Garcia C; Foulon S; Pagès A; Fizazi K
    Eur Urol Oncol; 2024 Oct; 7(5):1132-1140. PubMed ID: 38664139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early response monitoring during [
    Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.